Castle Biosciences (CSTL) Operating Expenses (2018 - 2026)

Castle Biosciences has disclosed Operating Expenses across 9 years of filings, most recently posting $106.6 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 17.89% year-over-year to $106.6 million; the TTM figure through Jun 2026 stood at $389.4 million (up 5.43% YoY), while the FY2025 annual figure was $387.0 million, up 19.68% from the prior year.
• Operating Expenses came in at $106.6 million for Q2 2026 at Castle Biosciences, up from $102.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $115.9 million in Q1 2025 to a low of $38.8 million in Q2 2022.
• Average Operating Expenses over 5 years is $78.7 million, with a median of $79.6 million recorded in 2024.
• Year-over-year, Operating Expenses jumped 89.57% in 2022 and slipped 11.93% in 2026.
• Over 5 years, Operating Expenses stood at $61.2 million in 2022, then advanced by 17.34% to $71.8 million in 2023, then climbed by 14.6% to $82.3 million in 2024, then advanced by 10.43% to $90.8 million in 2025, then gained by 17.37% to $106.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $106.6 million in Q2 2026, $102.1 million in Q1 2026, and $90.8 million in Q4 2025.